Acumen Pharmaceuticals, Inc.

you know, associations which has been done with other biomarkers such as tau-181 or 217 where, you know, where at least some modeling-based studies can tell you to what extent you might see a change, you might need to see a change in these two biomarkers so as to kind of have an impact in either CDR-SP or IDRS. Thanks.

Yeah, maybe I can try to take that one too. As far as the use of the IDRIS versus the CDR Summit boxes, one of the things that was interesting in the recent draft guidance was that they no longer called out the CDR Summit boxes. And they've actually presented it at public meetings, the idea that in the previous draft guidance where they did mention the CDR Summit boxes, they didn't mean to endorse that as sort of the only scale. But what they did say in this most recent draft guidance is that a scale that's a composite of cognitive measures and functional measures may have real utility. And that's what the IDRIS is. It's a combination of cognitive measures from the ADAS-COG and then functional measures from a scale called ADCS-ADL. So we think that is very positive, actually, in terms of our use of the IDRIS. I would assume that Lilly, since in the trailblazer studies, that's their primary, they were happy to see that. So, yeah, I think that's a really good clarification from FDA in terms of that, those kind of scales. In terms of correlations between plaque reduction and clinical benefit, I think what's really becoming a consensus opinion now is that you actually have to get plaque below a certain threshold. And this is something that we at Acumen have been saying for a long time, is that if you're going to target plaque, you have to basically get rid of it. And so the goal seems to be, based on existing data, that you want to get below 25, say, centilloids, or at most 30. So if you want to, if your target is plaque, that's what you need to do. But again, our target's not plaque. Our target is oligomer. So it'll be interesting to see what effects we have on plaque. But with our differentiated mechanism, that's really not the construct of our development plan. Thank you.

I show no further questions at this time. I would now like to turn the call back over to Alex Braun for closing remarks.